Role of gefitinib (G) in heavily pretreated non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Tamburini, E.
Tassinari, D.
Pasquini, E.
Papi, M.
Possenti, C.
Drudi, F.
Castellani, C.
Santelmo, C.
Carloni, F.
Ravaioli, A.
机构：
[1] Dept Oncol, Rimini, Italy
[2] Dept Oncol, Cattolica, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19102
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pemetrexed for Heavily Pretreated Patients With Advanced Non-small Cell Lung Cancer
    Lee, Jih-Hsiang
    Yu, Chong-Jen
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Lin, Yu-Lin
    Yang, Chih-Hsin
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2010, 109 (05) : 338 - 344
  • [2] Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC).
    Traynor, AM
    Schiller, JH
    Stabile, LP
    Kolesar, JM
    Belani, CP
    Hoang, T
    Dubey, S
    Eickhoff, J
    Marcotte, SM
    Siegfried, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 676S - 676S
  • [3] Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC)
    Dubey, S
    Siegfried, J
    Stabile, L
    Kolesar, J
    Belani, C
    Hoang, T
    Eickhoff, J
    Marcotte, S
    Schiller, J
    Traynor, A
    LUNG CANCER, 2005, 49 : S87 - S88
  • [4] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [5] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [6] Serum EGFR in patients with non-small cell lung cancer (NSCLC) treated with gefitinib
    Spreafico, A
    Gregorc, V
    Ludovini, V
    Pistola, L
    Amoroso, M
    Tofanetti, F
    Compagnoni, A
    Aondio, G
    Tonato, M
    Villa, E
    LUNG CANCER, 2005, 49 : S112 - S113
  • [7] Gefitinib and celecoxib in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel, SM
    Shehadeh, NJ
    Ruckdeschel, JC
    Chaplen, RA
    Belzer, K
    Wozniak, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 639S - 639S
  • [8] The BC Cancer Agency experience with gefitinib in advanced non-small cell lung cancer (NSCLC)
    Ho, C
    Murray, N
    Melosky, B
    Laskin, J
    Anderson, H
    Karim, RR
    Hamata, L
    Bebb, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 220S - 220S
  • [9] A phase II clinical and PET study of erlotinib and bexarotene for heavily pretreated advanced non-small cell lung cancer (NSCLC)
    Dragnev, K. H.
    Rigas, J. R.
    Seltzer, M.
    DiSalvo, W.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Dmitrovsky, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] BEVACIZUMAB AS A SALVAGE TREATMENT IN HEAVILY PRETREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS
    Hadoux, J.
    Angelergues, A.
    Bidault, F.
    Soria, J.
    Planchard, D.
    Le Chevalier, T.
    Massard, C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 151 - 151
12345